Pfizer's Read, Novo's Gruhn among those appointed to PhRMA board

> Pier Pharmaceuticals has appointed Peter Letendre as its CEO & president and his election to the board of directors. Pier release

> Par Pharmaceutical's John MacPhee has resigned his positions as president of Strativa Pharmaceuticals and executive VP of Par Pharmaceutical Companies to pursue other interests effective Jan. 31, 2011. Patrick LePore, Par's chairman, CEO and president, will assume day-to-day oversight of Strativa on an interim basis. Par release

> Medtronic ($MDT) Chairman and CEO William Hawkins will retire when the fiscal year ends April 29, 2011. The company's board of directors has initiated an external search for his replacement, and Hawkins plans to remain until his successor is appointed. News

> Valeant Pharmaceuticals CFO Peggy Mulligan has resigned a week after Chairman Bill Wells departed. Story

> China Botanic Pharmaceutical has named David Dong the company's new CFO. China Botanic release

> InterMune has appointed the following executives ahead of the European launch of Esbriet: senior VP and Managing Director, Europe Giacomo Di Nepi; senior Vice President, EU Medical and Global Medical Advisor Frank Weber; senior VP and general manager, Germany Markus Leyck Dieken; and VP, Sales and Marketing, Europe Manuela Maronati. InterMune release

> Celera has tapped Alfred Merriweather as senior VP and CFO. Celera release

> Icagen has announced that Seth Hetherington, SVP, Clinical and Regulatory Affairs, will be leaving the company at the end of the year. Following his departure, Greg Rigdon, VP, New Product Development, will assume leadership responsibility for the company's clinical development efforts. Icagen release

> Optimer Pharmaceuticals has reported that Gregory Papaz has joined Optimer as senior VP of Commercial Operations.  Optimer release

> Bausch + Lomb has named Rick Heinick as corporate vice president, Global Human Resources and Transformation, effective Jan. 4, 2011. Bausch + Lomb release

> The Pharmaceutical Research and Manufacturers of America (PhRMA) has elected of four new members to its board of directors: Ian Read, president and CEO, Pfizer; Jerzy Gruhn, president, Novo Nordisk; Mark Iwicki, president and COO, Sunovion Pharmaceuticals; and Staffan Schuberg, president, Lundbeck. PhRMA release

> Urodynamix Technologies has announced that Dave Rankin and David Raffa have been appointed to its board of directors and that Pierre Leduc, Barry Allan and Tanner Philp have stepped down as directors. Urodynamix release

> AcuMEMS has appointed Richard Ferrari as a new member of its board of directors. AcuMEMS release

> CEVEC Pharmaceuticals, the developer of the CAP protein expression system derived from human amniocytes, has announced that Rainer Christine has joined its supervisory board. CEVEC release

> C. Boyd Clarke has joined NovaDigm Therapeutics' board of directors. NovaDigm's release

> Auxilium Pharmaceuticals has named Peter Brandt to its board of directors as an independent director.  Auxilium release

> Lotus Pharmaceuticals has announced that Michael Toups, Lijun Fan, Zhaohui Li and Jun Lu have been appointed to serve on the company's board of directors. They will replace current directors Li Ping, Liu Jin, Xian Xuemei and Song Zhenghong. Lotus release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.